Dimethylformamide → 3-Methylcarboxy-6,7-dihydropyrido[3,2-b]thieno[2,3-d]oxepine
反応式
CO[C:3](=O)[C:4]1[CH:9]=[C:8]([O:10][CH2:11][CH2:12][C:13]2[CH:17]=[CH:16][S:15][CH:14]=2)[C:7](I)=[N:6][CH:5]=1.CN(C)C=O.[C:25](=O)([O-:27])[O-:26].[K+].[K+].C1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1>CO.C([O-])(=O)C.[Pd+2].C([O-])(=O)C>[CH3:3][C:4]1[C:5]([C:25]([OH:27])=[O:26])=[N:6][C:7]2[C:14]3[S:15][CH:16]=[CH:17][C:13]=3[CH2:12][CH2:11][O:10][C:8]=2[CH:9]=1参加物
7
反応物 4
生成物 1
試薬・触媒・溶媒 2
反応条件
- 温度
- 90 °C
実験手順
To a solution of 6-Iodo-5-(2-thiophen-3-yl-ethoxy)-nicotinic acid methyl ester (4.40 g, 11.3 mmol) in N,N-Dimethylformamide (176 mL, 2270 mmol) was added potassium carbonate (9.37 g, 67.8 mmol), triphenylphosphine (1.19 g, 4.52 mmol) and palladium acetate (508 mg, 2.26 mmol). The reaction mixture was stirred at 90° C. 8 h. The reaction mixture was diluted with MeOH then filtered through celite. The filtrate was concentrated. The crude product was purified by flash chromatography EtOAc/Hex (0-100%) (product eluted at 30%) to give 3-methylcarboxy-6,7-dihydropyrido[3,2-b]thieno[2,3-d]oxepine (52.8%). MS: (ESI+) 262.0
後処理
- custom8 h
- filtrationthen filtered through celite
- concentrationThe filtrate was concentrated
- customThe crude product was purified by flash chromatography EtOAc/Hex (0-100%) (product eluted at 30%)
出典と根拠
- ORDレコード
- ord-ee7a6cabb5254758bbea81f9cabdbe8a
- 出典データセット
- uspto-grants-2014_09
- 特許番号
- US08846762B2
反応ノート
読み込み中…